BIOTECHNOLOGY · REGULATION CROWDFUNDING
Millions of Americans suffer concussions each year. 1.4 to 4.2 million may never recover. Rest is not enough—and there are zero FDA-approved treatments. OXE103 is a first-in-class ghrelin therapy that showed an 85% responder rate in a Phase 2a trial. Supported by NFL quarterback Alex Smith and cornerback Richard Sherman, backed by $100+ million in development data by Daiichi Sankyo, and led by a team whose prior companies have achieved $9 billion in exits.
This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
